Matthew Pakizegee, PharmD, MS

Clinical Pathways GPS

Engaging Patients in Care Through Greater Access to Medical Records and Clinical Pathways

04/16/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Without interoperability of medical records between health systems, patients are the best chance for the medical system to provide continuity of care when medical records from a different health system are difficult...

...

04/16/2019

Journal of Clinical Pathways

Clinical Pathways GPS

CMS Policies Concerning CAR T-Cell Therapy

05/15/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

Chimeric antigen receptor (CAR) T-cell therapy is a new form of cancer therapy that uses a patient’s own immune system to fight the disease. This type of cell therapy uses an individualized process to develop a...

...

05/15/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Ramifications of “Medicare for All” and Implications for Clinical Pathways

08/19/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

As the Medicare for All (M4A) debate continues into 2020, clinical pathway organizations, payers, health systems, providers, and patients will all play a role in shaping future policies around patient access and...

As the...

08/19/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Speaker Pelosi’s Plan to Lower Drug Costs

11/18/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

As total cost of care increasingly becomes a major issue in the United States, both market solutions like clinical pathways and government solutions such as drug pricing regulations are being proposed. Each solution...

As...

11/18/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Proactive Steps to Ensure Appropriate Utilization of the First Disease-Modifying Therapy for Alzheimer Disease

03/16/2020

Matthew Pakizegee , PharmD, MS;

Jonathan W. Hodgson , MBA;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Chad McAuliffe ;

Widespread hope exists that aducanumab will soon gain Food and Drug Administration approval as the first disease-modifying therapy for patients with mild cognitive impairment associated with Alzheimer disease (AD),...

...

03/16/2020

Journal of Clinical Pathways

LTC GPS

The Ever-Expanding Role of Nurse Practitioners in LTC

06/20/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

With a projection short fall of between 46,900 and 121,900 physicians in the health care workforce by 2032, who will fill the gap?1 One answer could be nurse practitioners (NPs). NPs are advanced practice registered nurses (APRNs) who are...

With a projection short fall of...

06/20/2019

Annals of Long-Term Care

LTC GPS

Special Needs Plans Are Special for Long-Term Care

03/09/2020

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

In pursuit of elevating the quality of health care delivered, many care organizations and facilities have added a fourth aim—reducing caregiver burn out—to the classic Triple Aim in health care, which includes improving the health of...

In pursuit of elevating the...

03/09/2020

Annals of Long-Term Care

LTC GPS

The Ever-Expanding Role of Nurse Practitioners in LTC

10/21/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

APRNs are helping to mitigate the effects of the national physician shortage by serving as primary care providers (PCPs).

APRNs are helping to mitigate...

10/21/2019

Annals of Long-Term Care

Clinical Pathways GPS

Value-Based Clinical Pathways in the World of Reference-Priced Medicare Part B Drugs

12/13/2018

Matthew Pakizegee , PharmD, MS;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

The Centers for Medicare & Medicaid Services (CMS) released an advanced notice of proposed rulemaking on October 25, 2018, seeking to test  whether using a combination of 3 approaches—an international drug...

The...

12/13/2018

Journal of Clinical Pathways

Oncolytic Biosimilars: An Opportunity to Reduce Oncology Treatment Costs

Clinical Pathways GPS

04/21/2020

Craig Ornstein , PhD, MA;

Jamey Hardesty , MPH;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

Uttama Rath , PhD, MS;

Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...

...

04/21/2020

Journal of Clinical Pathways